CordenPharma Frankfurt Peptide Centre of Excellence

Core Capabilities

CordenPharma Frankfurt (DE) is a non-GMP R&D lab located on the Allessa industrial park in Frankfurt-Fechenheim, Germany that focuses on process development for peptide manufacturing via Solid-Phase Peptide Synthesis (SPPS). By providing R&D services in the peptide area, CordenPharma Frankfurt supplies seamless integration with our commercial-scale GMP peptide manufacturing in CordenPharma Brussels (BE) and CordenPharma Colorado (US).

The team, which is comprised of 75% PhDs in organic chemistry and 25% laboratory technicians, provides process development and non-GMP peptide manufacturing services to both internal & external customers.

  • >> Peptide Centre of Excellence for innovation and evaluation of new technologies
  • >> Solid-Phase Peptide Synthesis (SPPS) process development center
  • >> Liquid-Phase Peptide Synthesis (LPPS) for short peptides
  • >> Non-GMP Peptide manufacture from mg to multi 100 g (tox. studies, proof of concept)
  • >> Tailored development in projected scale for the CordenPharma GMP receiving site
  • >> Hands-on project execution on PhD level
  • >> SPPS Tech Transfer directly into GMP manufacturing
  • >> PMO and PPMO process development
  • >> Labelled peptides (cold labelling)
  • >> Peptide for cosmetic market
  • >> HPLC, development up to validation readiness

Related Products & Platforms

Technology Platforms

Facility Legacy

CordenPharma Frankfurt originates from the Heidelberg-based company ORPEGEN Peptide Chemicals which was founded as ORPEGEN GmbH in 1982. ICIG acquired the company assets and equipment in 2015 to form the CordenPharma Frankfurt R&D Peptide Centre of Excellence. In 2022 Astorg acquired CordenPharma from ICIG.

Head of Operations

Dr. Karsten Meyenberg

Corden Pharma International GmbH (Frankfurt)

Gebäude C26
Alt-Fechenheim 34
60386 Frankfurt am Main

Phone: + 49 (0)69 4109 2290
Fax: + 49 (0)69 4109 2324